SAN FRANCISCO, Jan. 27 - Ciphergen Biosystems said today it expanded its relationship with Pfizer to conduct protein biomarker studies.
Ciphergen will work with Pfizer in a hunt for markers from human serum for early detection of chronic obstructive pulmonary disease, according to Ciphergen. The studies will take place at Ciphergen's
Financial details of the agreement were not disclosed.
In 2001, Ciphergen and Pfizer began a study to look for biomarkers associated with drug safety.